Adicet Bio (ACET) Accumulated Expenses (2017 - 2026)

Adicet Bio's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 37.84% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $12.5 million (up 37.84% YoY), while the FY2025 annual figure was $5.6 million, down 20.81% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $12.5 million, up from $5.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $13.6 million in Q3 2024, with the low at $3.8 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $10.0 million (2022), against an average of $9.1 million.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses jumped 208.87% in 2022, then plunged 54.72% in 2025.
• Adicet Bio's Accumulated Expenses stood at $12.8 million in 2022, then advanced by 4.92% to $13.4 million in 2023, then sank by 47.09% to $7.1 million in 2024, then retreated by 20.81% to $5.6 million in 2025, then surged by 121.77% to $12.5 million in 2026.
• Business Quant data shows ACET's Accumulated Expenses at $12.5 million in Q1 2026, $5.6 million in Q4 2025, and $6.2 million in Q3 2025.